From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases

Untitled work

Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14

Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948

In vitro selection of RNA molecules that bind specific ligands

Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,845

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456

Most mammalian mRNAs are conserved targets of microRNAs

Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009) · Genome Research · doi:10.1101/gr.082701.108 · Cited by 8,462

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667

Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans

Wightman, B., Ha, I., & Ruvkun, G. (1993) · Cell · doi:10.1016/0092-8674(93)90530-4 · Cited by 4,292

Direct Gene Transfer into Mouse Muscle in Vivo

Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173

PLGA-based nanoparticles: An overview of biomedical applications

Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Breton, A. L., & Véronique Préat, A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 4,006

Silencing of microRNAs in vivo with ‘antagomirs’

Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949

CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes

Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696

The druggable genome

Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047

Asymmetry in the Assembly of the RNAi Enzyme Complex

Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922

RNAi

Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,751

The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme

Guerrier-Takada, C., Gardiner, K., Marsh, T., Pace, N., & Altman, S. (1983) · Cell · doi:10.1016/0092-8674(83)90117-4 · Cited by 2,684

CRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III

Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563

The Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones

Cech, T. R., & Steitz, J. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.008 · Cited by 2,524

mRNA-based therapeutics--developing a new class of drugs

Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474

Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337

Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena

Kruger, K., Grabowski, P. J., Zaug, A. J., Sands, J., Gottschling, D. E., & Cech, T. R. (1982) · Cell · doi:10.1016/0092-8674(82)90414-7 · Cited by 2,331

Treatment of HCV Infection by Targeting MicroRNA

Janssen, H. L. A., Reesink, H. W., Lawitz, E., Zeuzem, S., Rodriguez‐Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A. P., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,262

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206

An overview of the antimicrobial resistance mechanisms of bacteria

Reygaert, W. C. (2018) · AIMS Microbiology · doi:10.3934/microbiol.2018.3.482 · Cited by 2,152

Rational siRNA design for RNA interference

Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082

CRISPR–Cas9 Structures and Mechanisms

Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029

Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers

Hilton, I. B., D’Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3199 · Cited by 1,931

Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,829

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636

A guide to vaccinology: from basic principles to new developments

Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Benson, M. D., Waddington‐Cruz, M., Berk, J. L., Polydefkis, M. J., Dyck, P. J. B., Wang, A. K., Planté‐Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,483

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

Kay, M., Glorioso, J., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,444

The current state and future directions of RNAi-based therapeutics

Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

Bennett, C. F., & Swayze, E. E. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,431

Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?

Stein, C., & Cheng, Y. C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,300

An Unstable Intermediate Carrying Information from Genes to Ribosomes for Protein Synthesis

Brenner, S., Jacob, F., & Meselson, M. S. (1961) · Nature · doi:10.1038/190576a0 · Cited by 1,235

Editing DNA Methylation in the Mammalian Genome

Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R. A., & Jaenisch, R. (2016) · Cell · doi:10.1016/j.cell.2016.08.056 · Cited by 1,224

Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes

Matranga, C., Tomari, Y., Shin, C., Bartel, D. P., & Zamore, P. D. (2005) · Cell · doi:10.1016/j.cell.2005.08.044 · Cited by 1,211

Phage Response to CRISPR-Encoded Resistance in Streptococcus thermophilus

Deveau, H., Barrangou, R., Garneau, J. E., Labonté, J., Fremaux, C., Boyaval, P., Romero, D. A., Horvath, P., & Moineau, S. (2007) · Journal of Bacteriology · doi:10.1128/jb.01412-07 · Cited by 1,196

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175

Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system

Bikard, D., Jiang, W., Samai, P., Hochschild, A., Zhang, F., & Marraffini, L. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt520 · Cited by 1,145

Overcoming cellular barriers for RNA therapeutics

Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139

RNAi therapeutics: a potential new class of pharmaceutical drugs

Bumcrot, D. A., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,097

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094

mRNA is an endogenous ligand for toll-like receptor 3

Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062

Non-coding RNAs as drug targets

Matsui, M., & Corey, D. R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,042

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J., Montes, J., Vivo, D. C. D., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,039

Quantitative Analyses of SMN1 and SMN2 Based on Real-Time LightCycler PCR: Fast and Highly Reliable Carrier Testing and Prediction of Severity of Spinal Muscular Atrophy

Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,005

Applications of CRISPR technologies in research and beyond

Barrangou, R., & Doudna, J. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3659 · Cited by 1,005

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971

The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.

Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961

A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2

Monani, U. R. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1177 · Cited by 951

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909

Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy

Kim, D.-H., Behlke, M. A., Rose, S. D., Chang, M.-S., Choi, S., & Rossi, J. J. (2004) · Nature Biotechnology · doi:10.1038/nbt1051 · Cited by 903

Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle

Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 900

The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency.

Gallie, D. R. (1991) · Genes & Development · doi:10.1101/gad.5.11.2108 · Cited by 868

Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease

Kim, J., Hu, C., Achkar, C. M. E., Black, L. E., Douville, J., Larson, A. A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 852

RNA-Based Therapeutics: Current Progress and Future Prospects

Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818

CIRCLE-Seq: A highly sensitive in vitro screen for genome-wide CRISPR-cas9 nuclease off-targets

Tsai, S. Q., Nguyen, N. T., Malagon-Lopez, J., Topkar, V. V., Aryee, M. J., & Joung, J. K. (2017) · Nature Methods · doi:10.1038/nmeth.4278 · Cited by 814

Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing

Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J. M., Guo, J., Johnson, J. M., Lim, L. P., Karpilow, J. M., Nichols, K. E., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 804

Repurposing the CRISPR-Cas9 system for targeted DNA methylation

Vojta, A., Dobrinić, P., Tadić, V., Bočkor, L., Korać, P., Jülg, B. D., Klasić, M., & Zoldoš, V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw159 · Cited by 796

Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model

Hua, Y., Sahashi, K., Rigo, F., Hung, G., Horev, G., Bennett, C. F., & Krainer, A. R. (2011) · Nature · doi:10.1038/nature10485 · Cited by 744

Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine

Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P., & Lee, S. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.005 · Cited by 735

Host Immune System Gene Targeting by a Viral miRNA

Stern-Ginossar, N., Elefant, N., Zimmermann, A., Wolf, D., Saleh, N., Biton, M., Horwitz, E., Prokocimer, Z., Prichard, M., Hahn, G., et al. (2007) · Science · doi:10.1126/science.1140956 · Cited by 713

GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics

Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711

Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10

Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707

The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes

Freier, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.22.4429 · Cited by 697

Advances in mRNA Vaccines for Infectious Diseases

Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 696

Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.28 · Cited by 685

Sensing Small Molecules by Nascent RNA

Mironov, A. S., Gusarov, I., Rafikov, R., Errais, L. L., Shatalin, K. Y., Kreneva, R. A., Perumov, D. A., & Nudler, E. (2002) · Cell · doi:10.1016/s0092-8674(02)01134-0 · Cited by 682

Nonviral delivery of self-amplifying RNA vaccines

Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669

Functional annotation of native enhancers with a Cas9–histone demethylase fusion

Kearns, N. A., Pham, H., Tabak, B., Genga, R. M., Silverstein, N. J., Garber, M., & Maehr, R. (2015) · Nature Methods · doi:10.1038/nmeth.3325 · Cited by 656

Advances in the delivery of RNA therapeutics: from concept to clinical reality

Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656

Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

Shen, X., & Corey, D. R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 654

Silencing of microRNA families by seed-targeting tiny LNAs

Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O. J., Ruse, C. I., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 644

Patisiran: First Global Approval

Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0983-6 · Cited by 641

Aptamers as Therapeutics

Nimjee, S. M., White, R. R., Becker, R. C., & Sullenger, B. A. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104558 · Cited by 636

Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells

Czauderna, F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg393 · Cited by 632

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.001 · Cited by 622

A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

Sun, S.-H., Chen, Q., Gu, H.-J., Yang, G., Wang, Y.-X., Huang, X.-Y., Liu, S.-S., Zhang, N.-N., Li, X.-F., Xiong, R., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.020 · Cited by 617

Inhibition of hepatitis B virus in mice by RNA interference

McCaffrey, A. P., Nakai, H., Pandey, K., Huang, Z., Salazar, F. H., Xu, H., Wieland, S. F., Marion, P. L., & Kay, M. A. (2003) · Nature Biotechnology · doi:10.1038/nbt824 · Cited by 615

AAV-Mediated Gene Therapy for Research and Therapeutic Purposes

Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 609

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913147 · Cited by 608

Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA

Braasch, D. A., & Corey, D. R. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00058-2 · Cited by 604

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors

Dassie, J. P., Liu, X., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 600

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities

Vollmer, J., Weeratna, R. D., Payette, P., Jurk, M., Schetter, C., Laucht, M., Wader, T., Tluk, S., Liu, M., Davis, H. L., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324032 · Cited by 592

Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice

Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F., & Krainer, A. R. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.014 · Cited by 591

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice

Prakash, T. P., Graham, M., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 588

Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

Dhuri, K., Bechtold, C., Quijano, E., Pham, H. T. T., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 586

Sequence-specific inhibition of small RNA function

Hutvágner, G., Simard, M. J., Mello, C. C., & Zamore, P. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020098 · Cited by 584

New Vaccine Technologies to Combat Outbreak Situations

Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579

Design of antisense oligonucleotides stabilized by locked nucleic acids

Kurreck, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.1911 · Cited by 576

Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality

Elmén, J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki193 · Cited by 574

Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection

Wei, J., Alfajaro, M. M., DeWeirdt, P. C., Hanna, R. E., Lu-Culligan, W. J., Cai, W. L., Strine, M. S., Zhang, S.-M., Graziano, V. R., Schmitz, C. O., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.028 · Cited by 572

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus

Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013) · Scientific Reports · doi:10.1038/srep02510 · Cited by 565

Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565

Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy

Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J. E., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 560

The Structural and Functional Diversity of Metabolite-Binding Riboswitches

Roth, A., & Breaker, R. R. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.070507.135656 · Cited by 557

A Glycine-Dependent Riboswitch That Uses Cooperative Binding to Control Gene Expression

Mandal, M., Lee, M. N., Barrick, J. E., Weinberg, Z., Emilsson, G. M., Ruzzo, W. L., & Breaker, R. R. (2004) · Science · doi:10.1126/science.1100829 · Cited by 554

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.04.003 · Cited by 545

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Garrelfs, S. F., Frishberg, Y., Hulton, S. A., Koren, M. J., O’Riordan, W. D., Cochat, P., Deschênes, G., Shasha-Lavsky, H., Saland, J. M., van’t Hoff, W. G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021712 · Cited by 531

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530

RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection

Hu, W., Kaminski, R., Yang, F., Zhang, Y., Cosentino, L., Li, F., Luo, B., Alvarez-Carbonell, D., Garcia-Mesa, Y., Karn, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405186111 · Cited by 527

CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs

Mandegar, M. A., Huebsch, N., Frolov, E. B., Shin, E., Truong, A., Olvera, M. P., Chan, A. H., Miyaoka, Y., Holmes, K., Spencer, C. I., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.01.022 · Cited by 525

Gold Nanoparticles for Nucleic Acid Delivery

Ding, Y., Jiang, Z., Saha, K., Kim, C. S., Kim, S. T., Landis, R. F., & Rotello, V. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.30 · Cited by 521

Longitudinal effect of eteplirsen versus historical control on ambulation in D uchenne muscular dystrophy

Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., & Mercuri, E. M. (2015) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 519

Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza

Abbott, T. R., Dhamdhere, G. R., Liu, Y., Lin, X., Goudy, L., Zeng, L., Chemparathy, A., Chmura, S. A., Heaton, N. S., Debs, R. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.020 · Cited by 514

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases

Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507

Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses

Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501

The distributions, mechanisms, and structures of metabolite-binding riboswitches

Barrick, J. E., & Breaker, R. R. (2007) · Genome biology · doi:10.1186/gb-2007-8-11-r239 · Cited by 497

The growth of siRNA-based therapeutics: updated clinical studies

Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497

Eteplirsen in the treatment of Duchenne muscular dystrophy

Lim, K. R. Q., Maruyama, R., & Yokota, T. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s97635 · Cited by 496

Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target

Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008) · Science · doi:10.1126/science.1149859 · Cited by 491

Self-amplifying RNA vaccines for infectious diseases

Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487

Targeted Inhibition of miRNA Maturation with Morpholinos Reveals a Role for miR-375 in Pancreatic Islet Development

Kloosterman, W. P., Lagendijk, A. K., Ketting, R. F., Moulton, J. D., & Plasterk, R. H. A. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050203 · Cited by 466

DNA Vaccines—How Far From Clinical Use?

Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 466

Preclinical and clinical development of siRNA-based therapeutics

Özcan, G., Özpolat, B., Coleman, R. L., Sood, A. K., & Lopez‐Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 462

Specificity, duplex degradation and subcellular localization of antagomirs

Krützfeldt, J., Kuwajima, S., Braich, R. S., Rajeev, K. G., Pena, J., Tuschl, T., Manoharan, M., & Stoffel, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm024 · Cited by 462

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

McKay, P. F., Hu, K., Blakney, A. K., Samnuan, K., Brown, J. C., Penn, R., Zhou, J., Bouton, C. R., Rogers, P., Polra, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17409-9 · Cited by 462

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454

Combination of RT‐qPCR testing and clinical features for diagnosis of COVID‐19 facilitates management of SARS‐CoV‐2 outbreak

Wang, Y., Kang, H., Liu, X., & Tong, Z. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25721 · Cited by 451

siRNA Delivery Strategies: A Comprehensive Review of Recent Developments

Tatiparti, K., Sau, S., Kashaw, S. K., & Iyer, A. K. (2017) · Nanomaterials · doi:10.3390/nano7040077 · Cited by 444

Mapping the genomic landscape of CRISPR-Cas9 cleavage

Cameron, P., Fuller, C. K., Donohoue, P. D., Jones, B. N., Thompson, M. S., Carter, M. M., Gradia, S., Vidal, B., Garner, E., Slorach, E. M., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4284 · Cited by 443

Givosiran: First Approval

Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 441

Chemical modification and design of anti-miRNA oligonucleotides

Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 440

Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque

Li, B.-J., Tang, Q., Cheng, D., Qin, C., Xie, F. Y., Wei, Q., Xu, J., Liu, Y., Zheng, B.-J., Woodle, M. C., et al. (2005) · Nature Medicine · doi:10.1038/nm1280 · Cited by 431

Improved targeting of miRNA with antisense oligonucleotides

Davis, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl183 · Cited by 422

RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs

Bajan, S., & Hutvágner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 409

Riboswitches: Structures and MechanismsPreprint

Garst, A. D., Edwards, A. L., & Batey, R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003533 · Cited by 400

The Ribosome Is a Ribozyme

Cech, T. R. (2000) · Science · doi:10.1126/science.289.5481.878 · Cited by 382

Comparative Structure and Function Analysis of the RIG-I-Like Receptors: RIG-I and MDA5

Brisse, M. E., & Ly, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01586 · Cited by 379

Protection against lethal influenza virus challenge by RNA interference in vivo

Tompkins, S. M., Lo, C.-Y., Tumpey, T. M., & Epstein, S. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402630101 · Cited by 378

A CRISPR-based approach for targeted DNA demethylation

Xu, X., Tao, Y., Gao, X., Zhang, L., Li, X., Zou, W., Ruan, K., Wang, F., Xu, G., & Hu, R. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.9 · Cited by 377

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376

Phosphorothioate modified oligonucleotide–protein interactions

Crooke, S. T., Vickers, T. A., & Liang, X.-H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa299 · Cited by 372

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

Pasi, J., Rangarajan, S., Georgiev, P., Mant, T., Creagh, M. D., Lissitchkov, T. J., Bevan, D. H., Austin, S. K., Hay, C. R. M., Hegemann, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616569 · Cited by 369

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening

Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

Aartsma-Rus, A. M., & Krieg, A. Μ. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0657 · Cited by 364

Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs

Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 357

Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells

Liao, H., Gu, Y., Diaz, A., Marlett, J. M., Takahashi, Y., Li, M., Suzuki, K., Xu, R., Hishida, T., Chang, C.-J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7413 · Cited by 352

Untitled work

(2001) · PubMed Central · Cited by 342

A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines

Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338

Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments

Sekijima, Y. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308724 · Cited by 337

Cobomarsen, an oligonucleotide inhibitor of miR‐155, co‐ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T‐cell lymphoma

Seto, A. G., Beatty, X., Lynch, J. M., Hermreck, M., Tetzlaff, M. T., Duvic, M. A., & Jackson, A. L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15547 · Cited by 333

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy

Frank, D. E., Schnell, F. J., Akana, C., El-Husayni, S. H., Desjardins, C. A., Morgan, J. E., Charleston, J. S., Sardone, V., Domingos, J., Dickson, G., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009233 · Cited by 332

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D., Finke, C. M., Laborde, R. R., Wassie, E. A., Schimek, L., Hanson, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1310523 · Cited by 327

Golodirsen: First Approval

Heo, Y. (2020) · Drugs · doi:10.1007/s40265-020-01267-2 · Cited by 327

Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme

Krug, N., Hohlfeld, J. M., Kirsten, A., Kornmann, O., Beeh, K. M., Kappeler, D., Korn, S., Ignatenko, S., Timmer, W., Rogon, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411776 · Cited by 321

Induction of the interferon response by siRNA is cell type– and duplex length–dependent

Reynolds, A., Anderson, E. M., Vermeulen, A., Federov, Y., Robinson, K., Leake, D., Karpilow, J. M., Marshall, W. S., & Khvorova, A. (2006) · RNA · doi:10.1261/rna.2340906 · Cited by 317

Analysis of the host microRNA response to Salmonella uncovers the control of major cytokines by the let‐7 family

Schulte, L. N., Eulálio, A., Mollenkopf, H., Reinhardt, R., & Vogel, J. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.94 · Cited by 316

The Emerging Role of RNA as a Therapeutic Target for Small Molecules

Connelly, C. M., Moon, M. H., & Schneekloth, J. S. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.05.021 · Cited by 315

Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes

Veiga, N., Goldsmith, M., Granot, Y., Rosenblum, D., Dammes, N., Kedmi, R., Ramishetti, S., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06936-1 · Cited by 308

Inactivation of the Human Papillomavirus E6 or E7 Gene in Cervical Carcinoma Cells by Using a Bacterial CRISPR/Cas RNA-Guided Endonuclease

Kennedy, E. M., Kornepati, A. V. R., Goldstein, M., Bogerd, H. P., Poling, B. C., Whisnant, A. W., Kastan, M. B., & Cullen, B. R. (2014) · Journal of Virology · doi:10.1128/jvi.01879-14 · Cited by 302

MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment

Dorhoi, A., Iannaccone, M., Farinacci, M., Fae, K. C., Schreiber, J., Moura‐Alves, P., Nouailles, G., Mollenkopf, H., Oberbeck‐Müller, D., Jörg, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67604 · Cited by 302

On the art of identifying effective and specific siRNAs

Pei, Y., & Tuschl, T. (2006) · Nature Methods · doi:10.1038/nmeth911 · Cited by 298

Altered gene expression in plants due totrans interactions between homologous genes

Jorgensen, R. A. (1990) · Trends in biotechnology · doi:10.1016/0167-7799(90)90220-r · Cited by 289

CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections

van Diemen, F. R., Kruse, E. M., Hooykaas, M. J. G., Bruggeling, C. E., Schürch, A. C., van Ham, P. M., Imhof, S. M., Nijhuis, M., Wiertz, E. J. H. J., & Lebbink, R. J. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005701 · Cited by 289

Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals

McKinlay, C. J., Vargas, J. R., Blake, T. R., Hardy, J. W., Kanada, M., Contag, C. H., Wender, P. A., & Waymouth, R. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614193114 · Cited by 288

Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses

Bitko, V., & Barik, S. (2001) · BMC Microbiology · doi:10.1186/1471-2180-1-34 · Cited by 287

Anti-miRNA oligonucleotides: A comprehensive guide for design

Lima, J., Cerqueira, L., Figueiredo, C., Oliveíra, C., & Azevedo, N. F. (2018) · RNA Biology · doi:10.1080/15476286.2018.1445959 · Cited by 286

Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells

Zhou, J.-H., Swiderski, P., Li, H.-T., Zhang, J., Neff, C., Akkina, R., & Rossi, J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp185 · Cited by 284

A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin

Gallant‐Behm, C. L., Piper, J., Lynch, J. M., Seto, A. G., Hong, S. J., Mustoe, T. A., Maari, C., Pestano, L. A., Dalby, C. M., Jackson, A. L., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.11.007 · Cited by 283

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

Gaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa689 · Cited by 279

RNA therapeutics on the rise

Wang, F., Zuroske, T., & Watts, J. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00078-0 · Cited by 275

In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models

Yin, C., Zhang, T., Qu, X., Zhang, Y., Putatunda, R., Xiao, X., Li, F., Xiao, W., Zhao, H., Dai, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.012 · Cited by 273

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial

van der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S. B., van der Valk, M., Rietdijk, S. T., Molenkamp, R., Schinkel, J., van Nuenen, A. C., Beuers, U. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31715-9 · Cited by 271

Passive immunotherapy of viral infections: 'super-antibodies' enter the fray

Walker, L. M., & Burton, D. R. (2018) · Nature reviews. Immunology · doi:10.1038/nri.2017.148 · Cited by 268

Lomitapide and Mipomersen

Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 265

Genetic determinants of plasma triglycerides

Johansen, C. T., Kathiresan, S., & Hegele, R. A. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r009720 · Cited by 264

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells

Mitsuyasu, R. T., Merigan, T. C., Carr, A. D., Zack, J. A., Winters, M. A., Workman, C., Bloch, M. T., Lalezari, J. P., Becker, S., Thornton, L., et al. (2009) · Nature Medicine · doi:10.1038/nm.1932 · Cited by 263

Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria

Sardh, E., Harper, P., Balwani, M., Stein, P. E., Rees, D. C., Bissell, D. M., Desnick, R. J., Parker, C., Phillips, J. D., Bonkovsky, H. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1807838 · Cited by 259

miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide conjugates

Fabani, M. M., & Gait, M. J. (2007) · RNA · doi:10.1261/rna.844108 · Cited by 253

Review of CRISPR/Cas9 sgRNA Design Tools

Cui, Y., Xu, J., Cheng, M., Liao, X., & Peng, S. (2018) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-018-0298-z · Cited by 253

Delivery of therapeutic oligonucleotides with cell penetrating peptides

Boisguérin, P., Deshayes, S., Gait, M. J., O’Donovan, L., Godfrey, C., Betts, C., Wood, M. J. A., & Lebleu, B. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.008 · Cited by 251

Evolving landscape in the management of transthyretin amyloidosis

Hawkins, P. N., Ando, Y., Dispenzeri, A., González‐Duarte, A., Adams, D., & Suhr, O. B. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1068949 · Cited by 248

Locked nucleic acid: modality, diversity, and drug discovery

Hagedorn, P., Persson, R., Funder, E. D., Albæk, N., Diemer, S. L., Hansen, D. J., Møller, M. R., Papargyri, N., Christiansen, H., Hansen, B. R., et al. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.018 · Cited by 245

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

Corey, D. R. (2017) · Nature Neuroscience · doi:10.1038/nn.4508 · Cited by 242

In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials

Selle, K., Fletcher, J. R., Tuson, H. H., Schmitt, D. S., McMillan, L. J., Vridhambal, G. S., Rivera, A. J., Montgomery, S. A., Fortier, L., Barrangou, R., et al. (2020) · mBio · doi:10.1128/mbio.00019-20 · Cited by 242

Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications

Benizri, S., Gissot, A., Martin, A., Vialet, B., Grinstaff, M. W., & Barthélémy, P. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00761 · Cited by 241

An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

Erasmus, J. H., Khandhar, A. P., O’Connor, M. A., Walls, A. C., Hemann, E. A., Murapa, P., Archer, J., Leventhal, S., Fuller, J. T., Lewis, T. B., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9396 · Cited by 241

Induction of microRNA‐155 during Helicobacter pylori Infection and Its Negative Regulatory Role in the Inflammatory Response

Xiao, B., Liu, Z., Li, B., Tang, B., Li, W., Guo, G., Shi, Y., Wang, F., Wu, Y., Tong, W., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/605443 · Cited by 240

Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles

Sugo, T., Terada, M., Oikawa, T., Miyata, K., Nishimura, S., Kenjo, E., Ogasawara-Shimizu, M., Makita, Y., Imaichi, S., Murata, S., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.036 · Cited by 233

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Gouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00046-2 · Cited by 232

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels

Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz209 · Cited by 231

Formulation and Delivery Technologies for mRNA Vaccines

Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 228

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., & Perera, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400492-jlr200 · Cited by 227

The peptide nucleic acids (PNAs), powerful tools for molecular genetics and cytogenetics

Pellestor, F., & Paulasova, P. (2004) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201226 · Cited by 226

Exosome for mRNA delivery: Strategies and therapeutic applications

Iqbal, Z., Rehman, K., Mahmood, A., Shabbir, M., Liang, Y., Duan, L., & Zeng, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02634-x · Cited by 144

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics

Bian, X., Zhou, L., Luo, Z., Liu, G., Hang, Z., Li, H., Li, F., & Wen, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c11858 · Cited by 101

Using aptamers for targeted delivery of RNA therapies

Driscoll, J., Gondaliya, P., Zinn, D. A., Jain, R., Yan, I. K., Dong, H., & Patel, T. C. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.047 · Cited by 69

mRNA vaccines: a new era in vaccine development

Chandra, S., Wilson, J. C., Good, D. M., & Wei, M. Q. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.043987 · Cited by 58

Blockage of Osteopontin‐Integrin β 3 Signaling in Infrapatellar Fat Pad Attenuates Osteoarthritis in Mice

Dai, B., Zhu, Y., Li, X., Liang, Z., Xu, S., Zhang, S., Zhang, Z., Bai, S., Tong, W., Cao, M., et al. (2023) · Advanced Science · doi:10.1002/advs.202300897 · Cited by 45

An Insight on RNA Based Therapeutics and Vaccines: Challenges and Opportunities

Batra, K., Maan, S., & Sehrawat, A. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211118095451 · Cited by 4

Harnessing RNA molecules for therapy: advances in design, delivery, and clinical development

Zou, J., He, X., Li, Z., Song, B., Xing, X., Yu, J., & He, W. (2025) · Targetome · doi:10.48130/targetome-0025-0003 · Cited by 7

Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles

Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 95

RNA Therapeutics - History, Design, Manufacturing, and Applications

Louis, I. V.-S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102166 · Cited by 6

RNA-based therapeutics—Mechanisms and challenges

Khan, G. A., & Shahiwala, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27416-9.00007-1